The short version of systematic review fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-06 and is reviewed periodically as new material appears.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
=== Patient information === Blood Transfusion Leaflets (NHS Blood and Transplant) Blood Transfusion Leaflets (Welsh Blood Service) Blood Transfusion Information (Scotland) Blood Transfusion Information (Australia) Blood Transfusion Information (American Cancer Society)
AlphaFold's predicted structures are widely used in biological research, though the precise scale of that use is difficult to measure. More than 40% of protein-structure papers published in 2023 in Cell, Nature, and Science cited AlphaFold 2. A 2024 bibliometric analysis of the Web of Science database identified 1,680 peer-reviewed papers referencing AlphaFold published between January 2019 and May 2024. Measures of this kind rely on authors citing the AlphaFold papers when they use the tool, a convention encouraged but not enforced by the maintainers of the AlphaFold Protein Structure Database. Attempts to validate these counts against the full text of papers suggest that citations to foundational AlphaFold papers can both overstate and understate how widely the tool is used. In an analysis of about 8,900 papers in the PubMed Central Open Access corpus that mentioned AlphaFold, roughly 30% cited none of three foundational AlphaFold papers, while only about half of the papers citing at least one of those three mentioned AlphaFold anywhere in their text. A smaller manual check of 100 papers from a curated protein-literature database found a similar shortfall, with fewer than half of those mentioning AlphaFold including a formal citation.
Profilin allergy is significantly associated with respiratory allergy to grass pollen ( hay fever). After a person first becomes allergic to profilin through inhalation of grass or tree pollen, allergy to profilin-containing food and development of pollen-food syndrome occurs How often pollen-allergic people across Europe become profilin allergic varies widely; As of 1997, from about 5% of Swedish birch pollen–allergic people to 51% in Spanish people allergic to Mercurialis annua were profilin allergic. Profilin is the major allergen of certain food plants, for example, melon, orange, and soybean and thus allergy to melon, citrus fruits, tomato, and banana is a clinical marker of profilin hypersensitivity. As of 2018 there was no "solid therapeutic approach" to treat profilin allergy. As of 2018, the list of members of the profilin family identified as allergens contained:
== Radioactivity over time == Fission products have half-lives of 90 years (samarium-151) or less, except for seven long-lived fission products that have half-lives of 211,100 years (technetium-99) or more. Therefore, the total radioactivity of a mixture of pure fission products decreases rapidly for the first several hundred years (controlled by the short-lived products) before stabilizing at a low level that changes little for hundreds of thousands of years (controlled by the seven long-lived products). This behavior of pure fission products with actinides removed, contrasts with the decay of fuel that still contains actinides. This fuel is produced in the so-called "open" (i.e., no nuclear reprocessing) nuclear fuel cycle. A number of these actinides have half-lives in the missing range of about 100 to 200,000 years, causing some difficulty with storage plans in this time-range for open-cycle non-reprocessed fuels. Proponents of nuclear fuel cycles which aim to consume all their actinides by fission, such as the Integral Fast Reactor and molten salt reactor, use this fact to claim that within 200 years, their fuel wastes are no more radioactive than the original uranium ore. Fission products primarily emit beta radiation, while actinides primarily emit alpha radiation. Many of each also emit gamma radiation.
Sources: en.wikipedia.org
BK's early success in the field was overshadowed by a 1982 deal between McDonald's and The Walt Disney Company to promote Disney's animated films beginning in the mid-1980s and running through the early 1990s. In 1994, Disney switched from McDonald's to Burger King, signing a 10-movie promotional contract which would include such top 10 films as Disney Animation's Aladdin (1992), Beauty and the Beast (1991), The Lion King (1994), and Pixar's Toy Story (1995). Burger King created kids' meal toys to promote the DreamWorks Pictures film Small Soldiers (1998). This led to some controversy due to the film being rated PG-13. As a result, BK altered the promotional commercials to be directed at an older audience, and included a pamphlet disclaimer with the toys which read, in part; "the movie Small Soldiers may contain material that is inappropriate for younger children." A partnership in association with the Pokémon franchise at the height of its popularity in 1999 was tremendously successful for the company, with many locations rapidly selling out of the toys and the replacements. In December 1999, two hazardous incidents involving the Pokéball toy, one of which caused the death of a 13-month-old child, led to the toy being recalled. Shortly after the acquisition of Burger King by TPG Capital, L.P. in 2002, its new CEO Brad Blum set about turning around the fortunes of the company by initiating an overhaul of its flailing advertising programs.
=== Metabolic and proteomic evidence === Pro-oxidative processes correlate with pain in fibromyalgia patients. Decreased mitochondrial membrane potential, increased superoxide activity, and increased lipid peroxidation production are observed. The high proportion of lipids in the central nervous system (CNS) makes the CNS especially vulnerable to free radical damage. Levels of lipid peroxidation products correlate with fibromyalgia symptoms. Fibromyalgia is associated with the deregulation of proteins related to complement and coagulation cascades, as well as to iron metabolism. An excessive oxidative stress response may cause dysregulation of many proteins.
=== Bones, joints, frailty, posture and in people at risk === Strength training also provides functional benefits. Stronger muscles improve posture, provide better support for joints, and reduce the risk of injury from everyday activities. Progressive resistance training may improve function, quality of life and reduce pain in people at risk of fracture, with rare adverse effects. Weight-bearing exercise also helps to prevent osteoporosis and to improve bone strength in those with osteoporosis. For many people in rehabilitation or with an acquired disability, such as following stroke or orthopaedic surgery, strength training for weak muscles is a key factor to optimise recovery. Consistent exercise can actually strengthen bones and prevent them from getting frail with age.
The four substrates of this enzyme are eucalyptol, reduced nicotinamide adenine dinucleotide phosphate (NADPH), oxygen, and a proton. Its products are 2-exo-hydroxy-1,8-cineole, oxidised NADP+, and water. It is a cytochrome P450 protein containing heme.
The thorough pre-operative medical and surgical histories, and the physical examination of the patient's periorbital area (eyebrow-to-cheek-to-nose), determine if the patient can safely undergo a blepharoplasty procedure to feasibly resolve (correct or modify, or both) the functional and aesthetic indications presented by the patient. Sequentially, lower eyelid blepharoplasty can successfully address the anatomic matters of excess eyelid skin, slackness of the eye-muscles and of the orbital septum (palpebral ligament), excess orbital fat, malposition of the lower eyelid, and prominence of the nasojugal groove, where the orbit (eye socket) meets the slope of the nose. Concerning the upper eyelid, a blepharoplasty procedure can resolve the loss of peripheral vision, caused by the slackness of the upper-eyelid skin draping over the eyelashes; the outer and the upper portions of the field of vision of the patient are affected and cause him or her difficulty in performing mundane activities such as driving an automobile and reading a book.
Sources: en.wikipedia.org
== Adverse effects == The most prominent side effects are dizziness and sleepiness. Diphenhydramine is a potent anticholinergic agent and a potential deliriant in higher doses. This activity is responsible for the side effects of dry mouth and throat, increased heart rate, pupil dilation, urinary retention, constipation, and, at high doses, hallucinations or delirium. Other side effects include motor impairment (ataxia), flushed skin, blurred vision at nearpoint owing to lack of accommodation (cycloplegia), abnormal sensitivity to bright light (photophobia), sedation, difficulty concentrating, short-term memory loss, visual disturbances, irregular breathing, dizziness, irritability, itchy skin, confusion, increased body temperature (in general, in the hands or feet), temporary erectile dysfunction, and excitability, and although it can be used to treat nausea, higher doses may cause vomiting. Diphenhydramine in overdose may occasionally result in QT prolongation. Some individuals experience an allergic reaction to diphenhydramine in the form of hives. Conditions such as restlessness or akathisia can worsen from increased levels of diphenhydramine, especially with recreational dosages. Normal doses of diphenhydramine, like other first-generation antihistamines, can also make symptoms of restless legs syndrome worse. As diphenhydramine is extensively metabolized by the liver, caution should be exercised when giving the drug to individuals with hepatic impairment.
==== Gastronomy ==== In gastronomy, in situ refers to the art of cooking with the different resources that are available at the site of the event. Here a person is not going to the restaurant, but the restaurant comes to the person's home.
Philosophy of technology is a branch of philosophy that studies the "practice of designing and creating artifacts", and the "nature of the things so created". It emerged as a discipline over the past two centuries, and has grown "considerably" since the 1970s. The humanities philosophy of technology is concerned with the "meaning of technology for, and its impact on, society and culture". Initially, technology was seen as an extension of the human organism that replicated or amplified bodily and mental faculties. Marx framed it as a tool used by capitalists to oppress the proletariat, but believed that technology would be a fundamentally liberating force once it was "freed from societal deformations". Second-wave philosophers like Ortega later shifted their focus from economics and politics to "daily life and living in a techno-material culture", arguing that technology could oppress "even the members of the bourgeoisie who were its ostensible masters and possessors". Third-stage philosophers like Don Ihde and Albert Borgmann represent a turn toward de-generalization and empiricism, and considered how humans can learn to live with technology. Early scholarship on technology was split between two arguments: technological determinism and social construction. Technological determinism is the idea that technologies cause unavoidable social changes. It usually encompasses a related argument, technological autonomy, which asserts that technological progress follows a natural progression and cannot be prevented.
During this early period, the Monteith and Hackleman families were literally and politically on opposite sides of the fence. Residents in the Monteiths' portion of town were mainly Yankee merchants and professionals from the Upper Midwest and New England, who aligned with the Republican Party. They tended to sympathize with the Union during the Civil War. The residents in Hackleman's portion of town to the east were made up mostly of working-class Democrats from the Upland South/Lower Midwest who were split between supporting the Union and the Confederacy. The two sides planted a hedge near Baker Street separating their sides of town. With help from Samuel Althouse, the Monteiths built the first frame house in Albany in 1849. The Monteith House was considered the finest house in Oregon at the time. That same year the start of the California Gold Rush had caught the attention of the Monteith brothers, who provided supplies to the gold fields; their profits were seed money for several new businesses in Albany, including the general store. After the Monteiths developed these businesses, Albany became a major hub city in the Willamette Valley. Albany's first school was established in 1851 by the town's first physician, R. C. Hill. The first school teacher was Eleanor B. Hackleman, wife of Abram Hackleman. It was not until 1855 that a building was specifically erected for use as a school. In 1852, the first steamboat, the Multnomah, arrived and the first flour mill was built.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.